Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
    • Continuing Education
    • JNM Podcasts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Journal Claims
    • Corporate & Special Sales
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Reviewers
    • Permissions
    • Advertisers
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • View or Listen to JNM Podcast
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Follow JNM on Twitter
  • Subscribe to our RSS feeds
Research ArticleTheranostics

Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment

Luis David Jiménez-Franco, Gerhard Glatting, Vikas Prasad, Wolfgang A. Weber, Ambros J. Beer and Peter Kletting
Journal of Nuclear Medicine January 2021, 62 (1) 92-98; DOI: https://doi.org/10.2967/jnumed.120.245068
Luis David Jiménez-Franco
1ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH, Dresden, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gerhard Glatting
2Department of Nuclear Medicine, Ulm University, Ulm, Germany
3Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Vikas Prasad
2Department of Nuclear Medicine, Ulm University, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Wolfgang A. Weber
4Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ambros J. Beer
2Department of Nuclear Medicine, Ulm University, Ulm, Germany
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Peter Kletting
2Department of Nuclear Medicine, Ulm University, Ulm, Germany
3Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 62 no. 1 92-98
DOI 
https://doi.org/10.2967/jnumed.120.245068
PubMed 
32646878

Published By 
Society of Nuclear Medicine
Print ISSN 
0161-5505
Online ISSN 
2159-662X
History 
  • Received for publication March 13, 2020
  • Accepted for publication May 30, 2020
  • Published online December 17, 2020.

Article Versions

  • previous version (July 9, 2020 - 13:00).
  • You are viewing the most recent version of this article.
Copyright & Usage 
© 2021 by the Society of Nuclear Medicine and Molecular Imaging.

Author Information

  1. Luis David Jiménez-Franco1,
  2. Gerhard Glatting2,3,
  3. Vikas Prasad2,
  4. Wolfgang A. Weber4,
  5. Ambros J. Beer2 and
  6. Peter Kletting2,3
  1. 1ABX-CRO Advanced Pharmaceutical Services Forschungsgesellschaft mbH, Dresden, Germany
  2. 2Department of Nuclear Medicine, Ulm University, Ulm, Germany
  3. 3Medical Radiation Physics, Department of Nuclear Medicine, Ulm University, Ulm, Germany; and
  4. 4Department of Nuclear Medicine, Klinikum Rechts der Isar, Technische Universität München, Munich, Germany
  1. For correspondence or reprints contact: Peter Kletting, Department of Nuclear Medicine, Ulm University, D-89081 Ulm, Germany. E-mail: peter.kletting{at}uniklinik-ulm.de
View Full Text

Statistics from Altmetric.com

Cited By...

  • 19 Citations
  • 21 Citations
  • Google Scholar

This article has been cited by the following articles in journals that are participating in Crossref Cited-by Linking.

  • Absorbed Dose–Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
    Kévin Hebert, Lore Santoro, Maeva Monnier, Florence Castan, Ikrame Berkane, Eric Assénat, Cyril Fersing, Pauline Gélibert, Jean-Pierre Pouget, Manuel Bardiès, Pierre-Olivier Kotzki, Emmanuel Deshayes
    Journal of Nuclear Medicine 2024 65 6
  • Nephrotoxicity after radionuclide therapies
    Ashwin Singh Parihar, Sejal Chopra, Vikas Prasad
    Translational Oncology 2022 15 1
  • Theranostic digital twins for personalized radiopharmaceutical therapies: Reimagining theranostics via computational nuclear oncology
    Arman Rahmim, Julia Brosch-Lenz, Ali Fele-Paranj, Fereshteh Yousefirizi, Madjid Soltani, Carlos Uribe, Babak Saboury
    Frontiers in Oncology 2022 12
  • A Physiologically Based Pharmacokinetic Model for In Vivo Alpha Particle Generators Targeting Neuroendocrine Tumors in Mice
    Nouran R. R. Zaid, Peter Kletting, Gordon Winter, Vikas Prasad, Ambros J. Beer, Gerhard Glatting
    Pharmaceutics 2021 13 12
  • A physiologically based pharmacokinetic (PBPK) model to describe organ distribution of 68Ga-DOTATATE in patients without neuroendocrine tumors
    H. Siebinga, B. J. de Wit-van der Veen, J. H. Beijnen, M. P. M. Stokkel, T. P. C. Dorlo, A. D. R. Huitema, J. J. M. A. Hendrikx
    EJNMMI Research 2021 11 1
  • A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT)
    Kaat Spoormans, Melissa Crabbé, Lara Struelens, Marijke De Saint-Hubert, Michel Koole
    Pharmaceutics 2022 14 10
  • A PBPK model for PRRT with [177Lu]Lu-DOTA-TATE: Comparison of model implementations in SAAM II and MATLAB/SimBiology
    Valentina Vasić, Johan Gustafsson, Elham Yousefzadeh Nowshahr, Anna Stenvall, Ambros J. Beer, Katarina Sjögreen Gleisner, Gerhard Glatting
    Physica Medica 2024 119
  • A physiologically based pharmacokinetic model for [68Ga]Ga-(HA-)DOTATATE to predict whole-body distribution and tumor sink effects in GEP-NET patients
    Hinke Siebinga, Berlinda J. de Wit-van der Veen, Jos H. Beijnen, Thomas P. C. Dorlo, Alwin D. R. Huitema, Jeroen J. M. A. Hendrikx
    EJNMMI Research 2023 13 1
  • Challenges in developing response evaluation criteria for peptide receptor radionuclide therapy: A consensus report from the European Neuroendocrine Tumor Society Advisory Board Meeting 2022 and the ENETS Theranostics Task Force
    Vikas Prasad, Anna Koumarianou, Timm Denecke, Anders Sundin, Christophe M. Deroose, Marianne Pavel, Emanuel Christ, Angela Lamarca, Martyn Caplin, Justo P. Castaño, Clarisse Dromain, Massimo Falconi, Simona Grozinsky‐Glasberg, Johannes Hofland, Ulrich Peter Knigge, Beata Kos‐Kudla, Balkundi A. Krishna, Nicholas Simon Reed, Aldo Scarpa, Rajaventhan Srirajaskanthan, Christos Toumpanakis, Andreas Kjaer, Rodney J. Hicks, Valentina Ambrosini
    Journal of Neuroendocrinology 2025 37 2
  • Radiopharmaceutical transport in solid tumors via a 3-dimensional image-based spatiotemporal model
    Anahita Piranfar, Farshad Moradi Kashkooli, Wenbo Zhan, Ajay Bhandari, Babak Saboury, Arman Rahmim, M. Soltani
    npj Systems Biology and Applications 2024 10 1

Article usage

Article usage: July 2020 to April 2025

AbstractFullPdf
Jul 2020335022
Aug 2020163018
Sep 2020105017
Oct 20209104
Nov 20207708
Dec 20204993953
Jan 20215043532
Feb 20212042221
Mar 20211941712
Apr 2021154146
May 202113899
Jun 2021572418
Jul 2021353826
Aug 2021234425
Sep 2021282525
Oct 2021393552
Nov 2021253323
Dec 2021329052
Jan 2022366930
Feb 2022354428
Mar 2022203213
Apr 202285738
May 202283219
Jun 2022153521
Jul 202283419
Aug 2022185323
Sep 2022173435
Oct 202273324
Nov 2022102513
Dec 2022243212
Jan 2023134433
Feb 2023176123
Mar 202383813
Apr 202383716
May 2023122019
Jun 2023121714
Jul 2023101919
Aug 2023102213
Sep 2023103630
Oct 202372515
Nov 202332716
Dec 202333515
Jan 202473323
Feb 202443021
Mar 202453529
Apr 2024372840
May 2024224011
Jun 2024283417
Jul 2024212725
Aug 2024224320
Sep 202418429
Oct 202462423
Nov 2024144735
Dec 2024273817
Jan 2025272823
Feb 2025219912
Mar 2025247636
Apr 2025257130
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 62 (1)
Journal of Nuclear Medicine
Vol. 62, Issue 1
January 1, 2021
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
Luis David Jiménez-Franco, Gerhard Glatting, Vikas Prasad, Wolfgang A. Weber, Ambros J. Beer, Peter Kletting
Journal of Nuclear Medicine Jan 2021, 62 (1) 92-98; DOI: 10.2967/jnumed.120.245068

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Effect of Tumor Perfusion and Receptor Density on Tumor Control Probability in 177Lu-DOTATATE Therapy: An In Silico Analysis for Standard and Optimized Treatment
Luis David Jiménez-Franco, Gerhard Glatting, Vikas Prasad, Wolfgang A. Weber, Ambros J. Beer, Peter Kletting
Journal of Nuclear Medicine Jan 2021, 62 (1) 92-98; DOI: 10.2967/jnumed.120.245068
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Supplemental
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Computational Nuclear Oncology Toward Precision Radiopharmaceutical Therapies: Current Tools, Techniques, and Uncharted Territories
  • Mathematic Modeling of Tumor Growth During [177Lu]Lu-PSMA Therapy: Insights into Treatment Optimization
  • Absorbed Dose-Response Relationship in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with [177Lu]Lu-DOTATATE: One Step Closer to Personalized Medicine
  • Google Scholar

More in this TOC Section

Theranostics

  • Can 177Lu-DOTATATE Kidney Absorbed Doses be Predicted from Pretherapy SSTR PET? Findings from Multicenter Data
  • Evidence-Based Clinical Protocols to Monitor Efficacy of [177Lu]Lu-PSMA Radiopharmaceutical Therapy in Metastatic Castration-Resistant Prostate Cancer Using Real-World Data
  • 177Lu-Labeled Anticlaudin 6 Monoclonal Antibody for Targeted Therapy in Esophageal Cancer
Show more Theranostics

Basic

  • Dopamine D1 Receptor Agonist PET Tracer Development: Assessment in Nonhuman Primates
  • Optical Navigation of the Drop-In γ-Probe as a Means to Strengthen the Connection Between Robot-Assisted and Radioguided Surgery
  • Synthesis and Preclinical Evaluation of a 68Ga-Labeled Adnectin, 68Ga-BMS-986192, as a PET Agent for Imaging PD-L1 Expression
Show more Basic

Similar Articles

Keywords

  • minimal tumor perfusion
  • minimal receptor density
  • PBPK modeling
  • tumor control probability
  • 177Lu-DOTATATE
SNMMI

© 2025 SNMMI

Powered by HighWire